Co-Founder & Chief Medical Officer at @StoryHealthAI | Cardiologist @SutterHealth
San Francisco
Joined February 2009
- Tweets792
- Following340
- Followers272
- Likes448
Ashul Govil retweeted
Irrespective of HFrEF duration ⏱️
✅ ARNI works
✅ BB works
✅ MRA works
✅ SGLT2i works
To modify HF disease progression and ⬇️⬇️⬇️⬇️ ☠️/HF 🏨
Clinical benefits are additive, incremental, cumulative
Ashul Govil retweeted
Quantification of the lives that could be saved and worsened HF events that could be prevented if there was optimal implementation of SGLT inhibitors for HF globally
No time to wait
Benefits>>Potential Risks
doi.org/10.1002/ejhf.2864
Ashul Govil retweeted
GDMT for HF
Immediate vs delayed
Quadruple vs double or triple
Comprehensive vs incomplete
Target dosing vs suboptimal
The difference between
Optimal clinical outcomes vs events that could have been prevented but were unfortunately not
Ashul Govil retweeted
Wow! An SGLT2i is sold at $47.85!!!! (shipping included) 🥳🍾🎉🤑💸
That is 8% of the going price of empagliflozin or dapagliflozin!!
Caveat: Only indication in T2DM (not HF or CKD)
fiercepharma.com/pharma/ther…
@ChristosArgyrop @JonathanDavisHF @AndrewJSauer @hvanspall @dranulala
Ashul Govil retweeted
Join us July 31 from 4:30 - 5:30 PM PT for our webinar w/ @Intermountain,Transforming Heart Failure Care Delivery. Learn how our partnership affects heart failure care & improves patients' quality of life.
@Ashul
@KismetRasmu
@tomstanis
Register today:
us06web.zoom.us/webinar/regi…
Ashul Govil retweeted
“In chronic condition management, we have the unprecedented opportunity to leverage AI, remote care, & patient engagement apps to improve population health at scale; bringing care to those who need it most.”@ashul @MedEconomics #medtwitter #CardioTwitter
medicaleconomics.com/view/di…
Ashul Govil retweeted
SBP ⬇️ 23 mmHg
⬇️⬇️ CV events
Effectiveness of a non-physician community health-care provider-led intensive BP intervention versus usual care on cardiovascular disease (CRHCP): an open-label, blinded-endpoint, cluster-randomised trial - The Lancet thelancet.com/journals/lance…
Ashul Govil retweeted
Critical to deploy effective strategies to overcome inertia in use and dosing of GDMT
Have I mentioned there is inertia with ⬆️GDMT? Even with new CM? Even when enrolled in efforts to uptitrate GDMT?
CONNECT-HF demonstrates infrequent adjustments in GDMT and few at target doses after 1 year.
sciencedirect.com/science/ar…
Ashul Govil retweeted
"A key point conveyed in this analysis is that these patients need all the help they can get with maximally improving their clinical outcomes." @SJGreene_md @MKIttlesonMD #HFrEF tctmd.com/news/vast-majority…
Ashul Govil retweeted
Where does vericiguat fit for patients with HFrEF?
@gcfmd @SJGreene_md @JavedButler1 @_adevore @kofi_larry
jacc.org/doi/10.1016/j.jchf.…
Ashul Govil retweeted
If the dermatologist can start spironolactone for acne without even checking labs,
…perhaps you can stop discontinuing my patients’ spiro for K = 4.5
I’m here all day.
@AHajduczok
@DrMarthaGulati
@RyanTedfordMD
@ShelleyZieroth
Ashul Govil retweeted
Beautifully written design paper in @AmericanHeartJ for EMPACT-MI trial by @JLHarrington_MD from @DCRINews. #cardiology #cardiotwitter @jayudell @schuyler_jones @texhern @JavedButler1
Open Access: Empagliflozin in patients post myocardial infarction: Rationale and design of the EMPACT-MI trial.
#Cardiology
pubmed.ncbi.nlm.nih.gov/3559…
Ashul Govil retweeted
Internal Medicine residency graduates looking to match into cardiology may be interested in our 1-year non-accredited heart failure training program at @UHhospitals Harrington Heart & Vascular Institute and @CWRUSOM. (1/2)
Ashul Govil retweeted
Overwhelming efficacy!!!!!!
A little louder for the folks in the back!
@SantosGallegoMD @AHajduczok @robmentz @dranulala @DrMarthaGulati @hvanspall
This Post is from an account that no longer exists. Learn more
Ashul Govil retweeted
much of the estimated reduction in readmissions associated with HRRP can be attributed to reclassification of inpatient admissions to observation stays
@kejoynt
Accounting for Observation Stays in the Medicare Hospital Readmissions Reduction Program ja.ma/3EkxCSA
Ashul Govil retweeted
What do the book "Nudge" and behavioral economics have to do with optimizing EMR systems?
Find out in this excerpt featuring @yaleHFdoc from the Digital Health & Implementation Science #webinar with @MidAmericaHeart.
#medtwitter #CardioTwitter
vimeo.com/768731474
Ashul Govil retweeted
In a new #metaanalysis of 17 #RCTs investigating effects of dietary #sodium restriction on clinical outcomes in patients with #HeartFailure, Sodium restriction did not reduce risk of💀, 🏥, or composite of💀/🏥 @CircHF
bit.ly/3g34rLw
Ashul Govil retweeted
Swing by Booth #541 during the #HLTH2022 conference! Learn more about our digital hybrid care model and our partner @CaptionHealth.
@HLTHEVENT
Ashul Govil retweeted
❗Two weeks until #HLTH2022!❗
We're excited to showcase our partnership with @StoryHealthAI at @HLTHEVENT. Book some time with us to learn more about the impact early heart disease detection has when combined with a managed care optimization path ➡️ bit.ly/3TkFwBt
Ashul Govil retweeted
30% ☠️ at 2 years.
That’s a LOT of residual risk.
Much more work to do implementing #GDMTWorks
We need more urgency in addressing the treatment inertia.
Our patients need our help!
@SJGreene_md @dranulala @gcfmd @robmentz @RyanTedfordMD @DrMarthaGulati @NMHheartdoc
